



S. JORDAN ASSOCIATES

LIFE SCIENCES CONSULTANT & REGISTERED REPRESENTATIVE

CAPABILITIES BROCHURE

June 2026

For Institutional Investors Use Only

Securities are offered through Finalis Securities LLC Member FINRA/SIPC.
S. Jordan Associates and Finalis Securities LLC are separate, unaffiliated entities.



DISCLOSURE STATEMENT

This presentation, including without limitation any information, estimates or projections contained herein or made in connection with this presentation, either in writing or orally or other format, (this "Presentation") is being furnished by or on behalf of S. Jordan Associates ("Company"). Any information contained in this Presentation is for informational purposes only and has not been independently verified. The Presentation may contain confidential and/or proprietary information and is provided for the exclusive use of the recipient and may not be reproduced, provided or disclosed to others, or used for any other purpose, without written authorization by S. Jordan Associates and the Company, and upon request must be returned to the Company or S. Jordan Associates.

S. Jordan Associates is not a Broker/Dealer, Financial Analyst, Financial Bank, Securities Broker or Financial Planner, and any recipient of this Presentation acknowledges and agrees that S. Jordan Associates is not acting, nor is required to act, in any such capacity in connection with any transaction involving the Company pertaining to the matters contained herein. This Presentation is not intended to be and does not constitute financial advice or any other advice, is general in nature and not specific to any recipient. Recipients are responsible for their own investment research and investment decisions.

Recipients should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained on this Presentation constitutes a solicitation, recommendation, endorsement, or offer by the Company or S. Jordan Associates or any of their affiliates or any third party service provider to buy or sell any securities or other financial instruments in this or in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction. This Presentation does not address the circumstances of any particular individual or entity. S. Jordan Associates is not a fiduciary by virtue of any person's use of or access to this Presentation or the information contained herein. Recipients alone assume the sole responsibility of evaluating the merits and risks associated with the use of any information or other content in this Presentation before making any decisions based on such information or other content.

The Company, S. Jordan and Associates and their respective affiliates make no representation or warranty (express or implied) as to the accuracy or completeness of this Presentation and none of them will have any liability for any recipient's use of this Presentation or any other oral, written, or other communications transmitted to the recipient in the course of its evaluation of the Company, including without limitation, any improper use or defamatory, offensive, or illegal conduct of recipient or any other users. This Presentation is provided on an "as is" basis without warranties of any kind, either express or implied, including but not limited to warranties of title or implied warranties of merchantability or fitness for a particular purpose. The disclaimers of liability contained herein apply to any damages or injury caused by any failure of performance, error, omission, interruption, deletion, defect, delay in operation or transmission, computer virus, communication line failure, theft or destruction or unauthorized access to, alteration of, or use of record, whether for breach of contract, tortious behavior, negligence, or under any other cause of action. In exchange for accessing this Presentation, recipients agree not to hold Company or S. Jordan Associates or any of their affiliates or any third-party service provider liable for any possible claim for damages arising from any use by or decision made by recipients based on information or other content made available to recipients in or through this Presentation.

Any recipient of this Presentation acknowledges and agrees that the Company, S. Jordan Associates and their affiliates are not liable for any use of this Presentation or reliance on any information from this Presentation. In no event will the Company, S. Jordan Associates or any of their affiliates be liable for any direct, indirect, incidental, special, or consequential damages (including but not limited to lost profits or trading losses) arising out of the use of or inability to use this Presentation. S. Jordan Associates and their affiliates do not endorse and are not responsible for the accuracy or reliability of any opinion, advice, information or statement on this Presentation.

This Presentation includes certain forward-looking statements, estimates and projections provided by, and with respect to the anticipated future performance of, the Company. In some cases, recipients can identify forward-looking statements by terminology such as "may", "estimates", "anticipates", "intends", "will", "should", "could", "expects", "believes", or "predicts". Such statements, estimates, and projections reflect various assumptions and elements of subjective judgment made by management concerning anticipated results, which are subject to business, economic, and competitive uncertainties and contingencies, many of which are beyond the control of the Company and which may or may not prove to be correct. This Presentation contains certain projected financial information that reflects management's projections as to anticipated future results based upon assumptions that are inherently uncertain, including assumptions as to the size of the market in which it competes, general industry conditions, and other factors. The assumptions are based upon management's judgment. As a result, no representation or warranty is made as to the feasibility of the projected financial information included in this Presentation.

This Presentation is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction. Recipients should not regard this Presentation as a substitute for the exercise of their own judgment. The Company reserves the right to negotiate with one or more prospective third parties at any time and to enter into a definitive agreement relating to a transaction with the Company without prior notice to the recipient or other prospective third parties. Also, the Company reserves the right, at any time, to terminate the further participation in the investigation and process by any party and to modify any procedures without giving advance notice or providing any reason thereof. The Company also reserves the right during the evaluation period to take any action, whether within or outside the ordinary course of business. Neither this Presentation nor its delivery to recipients shall constitute or be construed to be an offer to sell any securities of the Company. Neither the Company nor S. Jordan Associates expects to update or otherwise revise this Presentation or other materials supplied herewith.



OPERATIONAL, BUSINESS DEVELOPMENT, AND BANKING EXPERIENCE



SCOTT JORDAN – Series 7

FOUNDER / CEO

Broker Dealer – Finalis Securities

<https://www.linkedin.com/in/sjordan1/>

- C-Level Operations Experience – Chief Financial Officer (CFO) / Chief Business Officer (CBO) for private and public (NASDAQ) biotechnology companies leveraging non-dilutive funding, strategic partnerships, and the capital markets to advance client development programs through proof-of-concept clinical studies
- Business Development / Investment Banking Expertise – Over 30 years of structuring licensing agreements, closing Seed / Series rounds, cross-over financings, equity lines, and S1 / S3 shelf offerings
- Facilitated "Exits" via Mergers and Acquisition (M&A), Initial Public Offerings (IPOs), and Alternative Public Offerings (APOs - Special Purpose Acquisition Companies - SPAC / reverse mergers)



COREY MENDOZA

CHIEF MARKETING OFFICER

<https://www.linkedin.com/in/coreymendoza/>

- An award-winning Executive Producer, Writer, Director, Editor, Designer, Musician, and Marketing Strategist with over 25 years of professional experience. His expertise is in brand development, marketing & advertising, video and television production, and creative design.

AWARDS:

- (5) Emmy Awards for "Minds of Medicine & "Vital Signs" (NATAS/Mid-Atlantic)
- (3) Telly Awards for "Best Production" in Television - "Gold Coast Reality"
- (5) Axiem Awards for "Absolute eXcellence" in Digital Media
- (3) Silver Mic Awards for Advertising Commercials
- (2) MarCom Creative for regional Advertising Campaign



CHRIS LEHMAN – Series 79

INVESTMENT BANKER

Broker Dealer – Finalis Securities / Collabrity

<https://www.linkedin.com/in/chrislehman/>

- Seasoned financial and business development executive in the life sciences industry with an exceptional combination of strategic partnering & financial leadership experience; 25+ years with venture-backed private and public industry leaders in therapeutics, diagnostics, CRO and industrial biotech
- Led or supported 28+ partnering and financing transactions totaling \$950 million
- Direct experience in leveraging broad industry network with investment banks, venture capital, equity research analysts and strategic pharmaceutical partners to raise dilutive and non-dilutive capital; conducted numerous presentations to potential investors and partners in the United States, Europe and Asia. Founded and grew a successful strategy advisory firm with 20+ client engagements



S. JORDAN ASSOCIATES (SJA) SERVICE OFFERINGS

NON-DILUTIVE FUNDING

S. Jordan Associates (SJA) is proficient identifying non-dilutive capital sources from Local, State (Cancer Prevention Research Institute of Texas - CPRIT) and Federally sponsored institutions (NIH / SBIR)

Guide clients through the application process and work collaboratively to implement best practices leading to successful awards



STRATEGIC ADVISORY/ BUSINESS DEVELOPMENT

SJA engages with strategic partners seeking to outsource R&D via traditional and novel partnerships (option-to-buy / licensing, co-development). Services provided to emerging growth companies include:

- Assessing the competitive landscape and benchmarking against industry deal averages (upfront payments, royalties, milestones)
- Targeted outreach to large biopharmaceutical, diagnostic, and medical device companies managed within SJA's proprietary Customer Relationship Management (CRM) system
- Negotiating term sheets with prospective partners optimizing client deal metrics and shareholder return on investment (ROI)

PRIVATE COMPANY FINANCINGS

SJA exceeds client financing objectives by accessing the company's extensive network of institutional, angel groups, and alternative investors (accredited, family offices, hedge funds) to finance early to mid-stage biotech companies through major value inflection points / milestones

Effective at negotiating and closing Seed / Series rounds with institutional capital sources (venture capital, cross-over) and identifying / securing commitments from "Lead" sponsors pivotal to securing investor syndicates



"EXITS" / PUBLIC COMPANY FINANCINGS

SJA works diligently evaluating viable exit / public company financing vehicles including mergers and acquisitions (M&A), initial public offerings (IPOs), and alternative public offerings (reverse merger, SPAC) aligned with capital market conditions and company-specific attributes

Alternative Public Offerings (APOs):

Leverage strong relationships with sell-side banks and reverse merger / SPAC sponsors identifying public shells, submitting proposals to win auctions, and negotiating / closing term sheets on behalf of private companies seeking to list on public market exchanges (e.g. NASDAQ)





ACHIEVEMENT 2024: RADIOPHARMACEUTICALS

Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform



ASSET SALES – IMAGINAB / TELIX PHARMACEUTICALS

- Telix announced asset acquisition from antibody engineering company ImaginAb, Inc. The acquisition includes a pipeline of next-generation therapeutic candidates, a proprietary novel biologics technology platform, and a protein engineering and discovery research facility to enhance existing innovation capabilities.
- Transaction delivers a pipeline of drug candidates against validated cancer targets including DLL3 and integrin $\alpha v \beta 6$, as well as a panel of other agents against novel targets in early discovery stage.
- The technology platform and intellectual property utilizes small, engineered antibody formats that enable highly specific targeting of cancer with radiation, that exhibit fast tumor uptake and clearance from the blood.
- This technology has the potential to be highly effective for imaging and treating tumors with a broad range of radioisotopes, with alpha emitters of particular interest.
- The ImaginAb capabilities combined with Telix's existing investments in new target development, conjugation and isotope processing has resulted in a platform that has the potential to rapidly create a new portfolio of "next generation" theranostic radiopharmaceuticals.

Jefferies

Syndicate
Banker



ACHIEVEMENTS 2021-2023: GENE THERAPY & IMMUNE-ONCOLOGY

NON-DILUTIVE FINANCING – INOMAGEN THERAPEUTICS

- S. Jordan Associates (SJA) acted as financial advisor to Inomagen Therapeutics assisting with securing a \$3.67M NIH SBIR Fast Track Phase 1/2 Grant to develop a novel gene therapy for Atrial Fibrillation (AF)
- The award includes \$462,689 from the National Heart, Lung, and Blood Institute (NHLBI) to complete the 'Phase 1' segment of development which includes optimizing gene doses and electroporation parameters required for atrial gene delivery
- Upon successful completion of the Phase 1 segment, Inomagen eligible to receive an additional \$3,212,600 in NIH funding to carry out the 'Phase 2' segment, which will include determining optimal dose of gene therapy required to attenuate established electrical remodeling in AF

ABOUT INOMAGEN THERAPEUTICS, www.inomagen.com

- Inomagen Therapeutics, Inc. is a privately held biotechnology company with technology licensed from Northwestern University (NU) dedicated to delivering the promise of gene therapy for treating serious cardiovascular diseases such as atrial fibrillation



**\$3.67M NIH SBIR
Fast Track Grant**



**Non-Dilutive
Funding**



PRIVATE COMPANY FINANCING – IMMUNOGENESIS

- S. Jordan Associates (SJA) acted as financial advisor to ImmunoGenesis assisting with raising a \$14.5M convertible note
- Lead investors include the founders of Chicago-based hedge funds (Magnetar Capital and Peak6), early-stage venture capitalists (BioAdvance, Texas Halo Fund) and secondary markets trading firm / cross-over investor (Adit Ventures)

ABOUT IMMUNOGENESIS, www.immunogenesis.com

- ImmunoGenesis formed to develop products from the lab of Dr. Michael A. Curran, Associate Professor, Department of Immunology at MD Anderson Cancer Center who worked closely with Nobel Laureate, Dr. James Allison, and is on the patent for CTLA-4 (cytotoxic T-lymphocyte-associated protein 4 – Ipilimumab / Yervoy) inhibition
- Development programs to overcome immune resistance in "cold" tumors unresponsive to current checkpoint inhibition therapies which comprise the majority of all cancers



**\$14.5M
Convertible Note**




**Private
Placement**



ACHIEVEMENTS: 2016 - 2020


NON-DILUTIVE FUNDING

- Secured awards from the Cancer Prevention Research Institute of Texas (CPRIT) resulting in ~\$35M of non-dilutive capital advancing three drug programs through Investigational New Drug (IND) enabling studies
- Leveraged non-dilutive capital during early stages of development to reach critical milestones resulted in subsequent financing rounds priced at higher valuations



STRATEGIC ADVISORY/ BUSINESS DEVELOPMENT

- Out-licensed South Korean rights to Salarium Pharmaceuticals / Iterion Therapeutics' lead compounds (*Secclidemstat*, *Tegavivint*) to HLB Lifesciences Co.
- Negotiated licensing terms including upfront payment, milestones, and royalties
- Established joint research committees monitoring progress and report findings to respective board members



PRIVATE COMPANY FINANCINGS

- Raised development funding from academic Institutions, angel groups, and accredited / institutional investors (venture capital)



"EXITS" / PUBLIC COMPANY FINANCINGS


- Identified, awarded, negotiated, and closed a term sheet / public shell with Flex Pharma (FLRX) resulting in Salarium Pharmaceuticals listing on NASDAQ via a reverse merger in 2019
- Facilitated a \$10.9M equity line with Aspire Capital, a private, long-only investment fund focused on making investments in publicly traded companies
- Closed a \$11M S1 offering with Ladenburg Thalmann funding Salarium through Phase 1 / 2 clinical milestones





TOMBSTONES: 2016 - 2020

SERIES 1



\$1.6M Convertible Note

SERIES A



\$6.4M Convertible Preferred

REVERSE MERGER



\$46.3M Deal Value

EQUITY LINE




\$10.9M In Common Stock

S1 OFFERING



\$11.0M In Common Stock

SERIES A1 / A2



\$10.0M Convertible Preferred

SERIES SEED



\$2M In Proceeds

S. KOREAN RIGHTS



\$1M Upfront Payment

Capital raises and licensing agreements facilitated as an executive (CFO / CBO) of Salarium Pharmaceuticals and Iterion Therapeutics



TRANSACTION HISTORY: 2005 - 2016



CLOSED \$583M IN LICENSING AGREEMENTS / PARTNERSHIPS

LICENSOR	TOTAL DEAL VALUE \$M	LICENSEE
ADVANCED LIFE SCIENCES™ Advancing Discoveries For Health	\$125	ANGELINI HOLDING
LIQUIDIA TECHNOLOGIES	\$200	gsk GlaxoSmithKline
NEOPHARM	\$50	NIPPON KAYAKU
IRX THERAPEUTICS UNLOCKING THE POWER OF IMMUNOTHERAPY	\$150	Celgene



RAISED \$152M – PRIVATE PLACEMENTS

DEAL VALUE \$M

\$15	\$60	\$6
calibra MEDICAL	Dicerna pharmaceuticals	PINNACLE BIOTECH

RAISED \$194 M – IPO / SECONDARY OFFERINGS / M&A

DEAL VALUE \$M

\$52 - IPO	\$74 - SECONDARY	\$6 - M&A
Corium	NEOPHARM	SmartPill™ The Measure of GI Health
		GIVEN IMAGING



AI / MACHINE LEARNING – IQ500

Securities are offered through Finalis Securities LLC Member FINRA/SIPC.
S. Jordan Associates and Finalis Securities LLC are separate, unaffiliated entities.



SJA PARTNERED WITH IQ500 – LEADER IN AI / MACHINE LEARNING



IQ500 connects Issuers, Investors, and Strategic Acquirers directly via an intelligent infrastructure that modernizes the entire private investment continuum from investment research and market analysis to relationship mapping, networking, opportunity screening, communication, transaction management, due diligence, FAQs, valuation, syndication, deal execution, benchmarking, performance measurement, and exit planning.

Powered by machine learning which accurately predicts investments with 93% statistical precision, IQ500 seeks to transform the efficiency of the \$480 billion Venture Capital market by streamlining investment selection, risk management, and outcome realization.

Machine Learning Algorithm: Trained on 2 million VC transactions using 160 million analytical arrays across 800-dimensional vectors

IQ500 VIDEO INTRODUCTION






IQ500 – RIGHT PERSON, RIGHT DEAL, RIGHT TIME




WHICH INVESTORS ARE BEST FOR THE COMPANY ?

Financial and strategic targets which are 93% likely to lead the Company's next transaction.



WHO DO WE CONTACT ? WHY? HOW?

Individual target contact affiliations. Direct, encrypted, "1:1" communication through MS Teams




WILL THERE BE INTEREST IN OUR DEAL ?

Real-time, "in aggregate" data of activity by financial and strategic targets on Company listing



WHEN WILL THE DEAL CLOSE ?

KPI's, including strength of relationships; deal quality; likelihood of success; timing of close.





IQ500 – BENEFITS FOR ISSUERS



Each Company listing on **IQ500** features a range of deal experiences — solving the most important problems — and intended to support financial and strategic success throughout the business horizon.

HOW DO WE COMPARE ?

Peer Groups which place each Company among its closest "competitors", as established by investors and strategic participants on Company's target lists.



Company	Revenue	EBITDA	Operating Profit	Net Income	Market Cap	EV	EV/EBITDA	EV/Operating Profit	EV/Net Income
Alkermes Inc.	128	25	10	5	14,500	14,500	580	140	280
Amgen Inc.	120	25	10	5	14,500	14,500	580	140	280
Novartis AG	115	25	10	5	14,500	14,500	580	140	280
Roche Holding AG	110	25	10	5	14,500	14,500	580	140	280
AbbVie Inc.	105	25	10	5	14,500	14,500	580	140	280
Merck & Co. Inc.	100	25	10	5	14,500	14,500	580	140	280
Johnson & Johnson	95	25	10	5	14,500	14,500	580	140	280
Pfizer Inc.	90	25	10	5	14,500	14,500	580	140	280
Novo Nordisk A/S	85	25	10	5	14,500	14,500	580	140	280
Sanofi S.A.	80	25	10	5	14,500	14,500	580	140	280
Boehringer Ingelheim AG	75	25	10	5	14,500	14,500	580	140	280
Dr. Reddy's Laboratories Ltd.	70	25	10	5	14,500	14,500	580	140	280
Abbott Laboratories	65	25	10	5	14,500	14,500	580	140	280
Amgen Inc.	60	25	10	5	14,500	14,500	580	140	280
Novartis AG	55	25	10	5	14,500	14,500	580	140	280
Roche Holding AG	50	25	10	5	14,500	14,500	580	140	280
AbbVie Inc.	45	25	10	5	14,500	14,500	580	140	280
Merck & Co. Inc.	40	25	10	5	14,500	14,500	580	140	280
Johnson & Johnson	35	25	10	5	14,500	14,500	580	140	280
Pfizer Inc.	30	25	10	5	14,500	14,500	580	140	280
Novo Nordisk A/S	25	25	10	5	14,500	14,500	580	140	280
Sanofi S.A.	20	25	10	5	14,500	14,500	580	140	280
Boehringer Ingelheim AG	15	25	10	5	14,500	14,500	580	140	280
Dr. Reddy's Laboratories Ltd.	10	25	10	5	14,500	14,500	580	140	280
Abbott Laboratories	5	25	10	5	14,500	14,500	580	140	280

WHAT IS OUR VALUATION ?

EXIT PATH ?

Precedent Transactions, Public Comparables



WHAT IS HAPPENING IN OUR MARKET ?

WITH INVESTORS, BUYERS, PEERS ?

Customized market data, competitive analysis, news, social sentiment.





OPTIMIZE INVESTOR TARGET LISTS / ENGAGEMENT / CLOSING






MARKETING / HUBSPOT (CRM)

Securities are offered through Finalis Securities LLC Member FINRA/SIPC.
S. Jordan Associates and Finalis Securities LLC are separate, unaffiliated entities.



MARKETING: NURTURING RELATIONSHIPS THROUGH EMAIL CHANNEL





EMAIL MARKETING STRATEGY: OPTIMAL MESSAGE, AUDIENCE, TIME



MESSAGING CONTENT

- General Outreach / Brand Recognition
- News Update
- Event Sign Up
- Collaboration
- Capital Raising / Partnering

TARGETED AUDIENCE

- Investors
- Strategic Partners
- Key Opinion Leaders
- Bankers

TIMING

- Highest Open Rate
- Highest Engagement Rate
- Campaign Specific Time Sensitivity

S. JORDAN ASSOCIATES
LIFE SCIENCES CONSULTING & REGULATORY REPRESENTATIVE

The **Translational Genomics Research Institute (TGEN)** and affiliate of City of Hope, a nonprofit medical research institute dedicated to conducting groundbreaking research, would like to schedule a meeting to discuss their novel pre-clinical CDK7 program.

CDK7 regulates cell cycle and super-enhancer dependent oncogene expression and is correlated with poor prognosis in many cancers (e.g. breast, gastric, hepatocellular, epithelial ovarian, pancreatic cancers).

tgen @ City of Hope

TGEN's... molecule... <100 nM), selective... with... ability. The drug... tumor growth as a single... xenograft... Ovarian, AML), and in combination with other agents...
 TGN-101... a 'non-covalent inhibitor' which binds... This is a significant... advantage to covalent... clinical trials... (e.g.... (2) which bind irreversibly given... a... protein... in transcription / cell cycle in normal... result of TGN-101... safety profile...
 Below are links to the company's non-confidential deck and Calendly if you would like to schedule a call with TGEN to learn more about this promising small molecule program.

[TGEN presentation](#)

[Schedule a call](#)

Regards,
 Scott Jordan
 S. Jordan Associates
www.sjordanassociates.com
scott@sjordanassociates.com



UTILIZING HUBSPOT DATA TOOLS (CRM) TO MEASURE SUCCESS



METRICS

DELIVERY RATE

- Delivered
- Bounced
- Spam

OPEN RATE

- Desktop Vs. Mobile
- Email Providers

EMAIL VIEW TIME

- Read
- Skimmed
- Glanced



CLICKS

HTML CLICK MAP

- Location Of The Clicks On The Email
- Optimization(s) For Button, Links, Graphics

CLICKED LINK(S)

- Content Clicked

LEAD SCORING

- Content engagement score for prioritization

AUTO-ADVANCE LIFE CYCLE STAGES

- Leads
- Scheduled a call
- Won / lost


DASHBOARD

- Performance review
- Team discussion



DATA IS POWER

FOLLOW UP COMMUNICATIONS



Ensure conversations and activities connected to the contact database for continuous learning and optimization?





ALTERNATIVE PUBLIC OFFERINGS (APOs)

Securities are offered through Finalis Securities LLC Member FINRA/SIPC.
S. Jordan Associates and Finalis Securities LLC are separate, unaffiliated entities.



APO SERVICES: INCEPTION TO CLOSING

APO COORDINATION

S. Jordan Associates manages APO Process on Behalf of Reverse Merger Sponsors (Banks) / Private Companies Including the facilitation of Public Company Readiness and Capital Supporting Transactions



LEGAL / PUBLIC COMPANY READINESS

LEGAL

- Legal advice and document preparation / negotiation including M&A, tax and securities law
- SEC disclosure and periodic reporting guidance

STEPHEN ALICANTI



FINANCE / INTERIM C-LEVEL

- Evaluation and implementation of financial controls
- Recruiting and leading the internal accounting and finance team members
- Investor and public relations strategies and leadership

STEVE JOSEPH



ACCOUNTING / CONTROLS

- Audit readiness
- S-4 prep (F Pages, MDA, Pro Forma)
- Internal controls
- Accurate, reliable and timely KPI and financial reporting

MIKE MONTGOMERY



PROJECT MANAGEMENT / CAPITAL SUPPORT

INVESTMENT BANKING

- Forecasting and financial / cash flow modeling
- Capital raises including venture capital (Series A>), concurrent and cross-over financings (PIPES), and public market offerings (S1, S3)
- Introduction to reverse merger sponsors
- Term sheet negotiations

Scott Jordan



Close

Affiliated Partners



APO WEBINAR

STRONG TRACK RECORD OF FACILITATING APO'S IN THE LIFE SCIENCES INDUSTRY

APO Webinar, "Reverse Mergers and SPACS:

"Are Alternative Public Offerings the New Normal For Biotech's Going Public?" – March 18th, 2021 <https://hubs.ly/H0JLhtK0>



SCOTT JANSSEN

Managing Director
LS Associates

Previously, part of the broader LifeSci Partner platform supporting over 200 clients with IR, PR, partnering / BD , and virtual CFO services



MIKE MONTGOMERY

Managing Partner
Effectus Group

Public filings, audit preparation, mergers and acquisitions, business combinations, financial due diligence, and integration



SCOTT JORDAN

Founder / CEO
S Jordan Associates

Raise private placements and concurrent financings, licensing / partnership agreements, M&A, and APOs – Reverse / SPAC



APO PUBLIC READINESS CHECKLIST

Strategic

- Have you built an IPO or Reverse Merger roadmap with specific subject matter experts, work stream, and milestones?
- Who is the project owner / manager and do they have experience with this complex process?
- Has the board reviewed the plan and key dates?
- Have you performed a Board "audit" to make sure you have the people, skills, and governance in place to lead a company into and operate effectively as a public company?
- Are the internal shareholders and experts on the Board held accountable for their portion of the project?
- Have you engaged a team of expert consultants to support the project (e.g. attorney's, financial and technical accounting, consultants, auditors, D&O insurance providers)?
- Have you prepared accurate, reliable, and timely financial and scientific reports that will be required as a public company?
- Do you have reliable forecasting and subsequent actual to forecast reporting?

Finance / Accounting

- Reviewed monthly closing book process / gap analysis necessary?
- Team in place to implement financial planning and analysis including the review of budgt vs. actual processes?
- Audited financials? If not, has the company received quotations from potentail auditing firms?
- Company discussed with management / Board final selection of auditors?
- Company worked with auditors / director of finance from an accounting firm to complete the audit?
- Completed a 409A valuation that can be substantiated under PCAOB standards?
- Reviewed the cap table ensuring all supporting documentation in place including all financial transactions?
- Set up data base to collect company information such as contracts, stock option grants, financial statements for efficient audit process?

Capital Raise

- Developed a plan and timeline for next financing?
- Completed an investor deck review by Investor Relations and financial experts ensuring synergistic with financial forecasts and budget?
- Reviewed 5 / 10-year financial plan and balance sheet?
- Reviewed a list of possible Series / Cross-over investors and selected a banker to assist with the process?
- Initiated the IPO / Reverse Merger roadmap with estimated timelines, assigned workstreams to stakeholders and consultants?



APPENDIX #1 – SJA PRIVATE PLACEMENT SERVICES AND TIMELINES

Securities are offered through Finalis Securities LLC Member FINRA/SIPC.
S. Jordan Associates and Finalis Securities LLC are separate, unaffiliated entities.




SJA SERVICE OFFERINGS

LEVEL	MONTHLY ENGAGEMENT FEE (\$)	SJA SUCCESS FEE (%)	COMPANY PROFILE: FUNDING ROUND / STAGE OF DEVELOPMENT; SERVICES PROVIDED	SERVICE OFFERINGS	DESCRIPTION / AFFILIATED PARTNERS
1	\$1,250	No	<ul style="list-style-type: none"> ➤ Funding Round: Seed – Series Rounds ➤ Stage of Development: Pre / Clinical ➤ Services: Private Placements, M&A (Client Directed) 	<ul style="list-style-type: none"> ➤ IQ500 	Client Subscription
2	\$4,000 - \$6,000	Yes	<ul style="list-style-type: none"> ➤ Funding Round: Seed – Series Rounds ➤ Stage of Development: Pre / Clinical ➤ Services: Private Placements (506b/c, RegCF), Business Development / Licensing 	<ul style="list-style-type: none"> ➤ SJA ➤ IQ500 ➤ Finalis ➤ StartEngine 	IQ500 – Client Subscription with SJA In Supervisory Role Optional: Investor Syndication Through Finalis Broker Dealer Network
3	\$8,000 – 10,000	Yes	<ul style="list-style-type: none"> ➤ Funding Round: Series A / B ➤ Stage of Development: Pre / Clinical ➤ Services: Valuations, Fairness Opinions, Private Placements, M&A, Business Development / Licensing, Non-Dilutive Capital 	<ul style="list-style-type: none"> ➤ SJA ➤ IQ500 ➤ Collabrity 	Full Investment Banking Engagement Leveraging AI / SJA Strategic Partner Investor Networks. Human Capital through Collabrity
4	\$15,000	Yes	<p>Services:</p> <ul style="list-style-type: none"> ➤ Private Companies: Alternative Public Offerings (APOs), PIPES, Pre-IPO Prep ➤ Public Companies: Reverse Splits / Stock Exchange Compliance 	<ul style="list-style-type: none"> ➤ SJA ➤ Collabrity 	Channel Partner, Collabrity, Available to Assist with Pre-IPO Readiness / Crossover Financings



PRIVATE PLACEMENT TIMELINE






FINALIS SECURITIES / SYNDICATION



Syndicate Capital Raises / M&A within Finalis' Broker Dealer Network

The Finalis Network Footprint

417 U.S. Affiliates with Approved Registration in all 50 States




West	142 Affiliates
South	131 Affiliates
Northeast	107 Affiliates
Midwest	37 Affiliates

Plus 170 affiliates with worldwide presence in the following countries

Brazil, Canada, Chile, Cyprus, Denmark, France, Germany, Guernsey, Hong Kong, Israel, Netherlands, Poland, Portugal, South Korea, Sweden, Switzerland, UK.

Number of Active Deals by Transaction Type

1,931 Active Transactions within the Finalis Network





APPENDIX #2 – ALTERNATIVE PUBLIC OFFERING (APO) CASE STUDY

securities are offered through S. Jordan & Associates Securities LLC Member FINRA/SIPC.
S. Jordan & Associates Securities LLC are separate, unaffiliated entities.




SALARIUS PHARMACEUTICALS REVERSE MERGES INTO FLEX PHARMA

- Salariaus Pharmaceutical (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced closing a merger with Flex Pharma, Inc.'s wholly owned subsidiary on July 19, 2019
- The newly combined company focused on the continued development of Salariaus' clinical pipeline, which targets rare, orphan cancers with lead compound, Seclidemstat, a LSD1 inhibitor (epigenetics validated target)
- Healthios Capital Markets (now Third500 <https://www.third500.com/>) served as financial advisor in the transaction to Salariaus Pharmaceuticals and Wedbush PacGrow advised Flex Pharma

Allocation Percentage - from Summary of Proposed Terms	\$M	%	
Flex Enterprise Value - "Shell"	\$7.2		} FLEXPharma
Flex Cash at Close	\$3.1		
Flex Total Fair Value	\$10.3		
Salariaus Total Fair Value	\$36.0		→ Salariaus PHARMACEUTICALS
Total Fair Value of Newco	\$46.3		→ \$46.3M DEAL VALUE
Allocation Percentage			
Flex		22.3%	
Salariaus		77.7%	



TIMELINE / MILESTONES FROM INCEPTION TO REVERSE MERGER CLOSING



Similar results are not guaranteed; based on investor demand and general market factors.



S. JORDAN ASSOCIATES

APPENDIX #3 – IQ500 / SJA SERVICES

Securities are offered through Finalis Securities LLC Member FINRA/SIPC.

S. Jordan Associates and Finalis Securities LLC are separate, unaffiliated entities.



SERVICE OFFERINGS

SERVICE	DESCRIPTION	PRICE	
IQ500 Monthly Subscription	Access to IQ500 – Profile, Top 100 Investors, Strategic Partners, Data Room	\$1,250 / Mo.	Cancellable Monthly
Document Review	Executive Summary, Management Presentation, Financial Model	\$5,000	Optional
Document Development	Executive Summary, Management Presentation	\$15,000	Optional
Financial Model Development	Progressive To “Peak” Value	\$20,000	Optional
EcoSystem Review	Network, Relationships, Targets, Peers, Exit Comps, M&A Precedents	\$2,500	Optional
Network Development	Warm Introductions, Referrals, Notifications	\$2,500 / Mo.	Optional
Deal Monitoring	Performance Tracking, Benchmarking, Data Analysis, Reporting	\$1,000 / Mo.	Optional
Deal Management	Network Development, Deal Monitoring, Plus Target Engagement	\$5,000 / Mo.	Optional
Total Listing Management	All The Above	\$7,500 / Mo.	Optional
Deal Syndication	For Issuers And VC's	% Spread	Optional
Secondary Transactions	For Issuers And VC's	% Spread	Optional



S. JORDAN ASSOCIATES

Life Sciences Consultant & Registered Representative

SCOTT JORDAN
Founder / CEO

512 N. McClurg #4604
Chicago, IL 60611

312-451-6210
scott@sjordanassociates.com
www.sjordanassociates.com



@sjordan1



@sjordanassociat